Wedbush maintains IDEAYA Biosciences at Outperform, raises price target to $63 from $60

IDEAYA Biosciences reported a Q3 2026 net loss of $125.7M, up from $112.5M in Q2, with collaboration revenue rising to $10.2M. Cash reserves fell to $1.15B. The company submitted darovasertib for FDA approval and plans Phase 3 trials, maintaining its cash runway guidance into 2030.

IDEAYA Biosciences, Inc. (IDYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update • Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanom

IDEAYA Biosciences reported Q3 GAAP EPS of -$1.22, missing estimates by $0.03, but revenue of $10.24M beat expectations by $2.66M. The company had $1.15B in cash and equivalents as of September 30, 2026, with its cash runway guidance into 2030 remaining unchanged.

IDEAYA Biosciences reported Q3 2026 results, highlighting NDA submission for darovasertib in metastatic uveal melanoma and positive clinical data for darovasertib and IDE849 at ESMO 2026. The company has $1.15B in cash and expects runway into 2030. IDEAYA plans to initiate Phase 3 trials for IDE849 and provided updates on its MTAP pathway programs. (IDYA)

IDEAYA Biosciences reported Phase 1 results for IDE849, showing antitumor activity in relapsed small cell lung cancer. Median overall survival was 17.4 months in second-line SCLC and 14.7 months across second-line and later-line patients. The confirmed response rate was 60.8% in second-line SCLC. IDEAYA plans Phase 3 trials. The stock closed at $36.12, up 1.83%, and is down 0.03% in premarket trading.

IDEAYA Biosciences (NASDAQ:IDYA) shared Phase 1 trial results for IDE849, showing promising survival and response rates in lung cancer and neuroendocrine tumors. The study, presented by partner Hengrui, reported median overall survival of 17.4 months in second-line small cell lung cancer patients. IDEAYA plans Phase 3 trials following FDA meetings.